Alan Bash named president of Carvykti at Legend

Legend Biotech Corp. (NASDAQ:LEGN) named Alan Bash president of Carvykti, a newly created role focusing on the BCMA-targeted CAR T cell therapy ciltacabtagene autoleucel. Bash previously held CEO roles at ZielBio Inc. and Checkmate Pharmaceuticals Inc. Carvykti was FDA approved in 2022 to treat relapsed or refractory multiple myeloma and has been dominating the market. 

CureVac N.V. (NASDAQ:CVAC) hired Axel Malkomes as CFO. Malkomes was CFO of Cardior Pharmaceuticals GmbH and succeeds Pierre Kemula, who left on Oct. 31...